CS MEDICA A/S announces a new distribution partnership with Pharma Avanti, designated as the preferred partner for its subsidiary, CANNORDIC, in Brazil. This alliance signals a strategic move into Brazil's growing pain relief and CBD market and positions Brazil as a gateway for expanding into the broader South American market.

Highlighting the financial impact of this partnership, CANNORDIC has secured an initial order post-regulation 327 approval with ANVISA, consisting of 50,000 units, spanning several innovative products, including Pain & Arthritis Gel, Psoriasis Gel, Pain Patch (8 patches), Nasal Spray Night, and PSOR + ATOPIC Lotion. This order is valued at €313,000 for the first year, showcasing revenue potential from this new market entry, post-product registration*.
 

Strategic Importance of the Brazilian Market

Brazil is a pivotal market for CS MEDICA due to its size, progressive health policies concerning CBD, and compliant, innovative approach to pain management. Brazil's strategic location and advanced regulatory environment make it an optimal gateway for introducing CANNORDIC's cannabinoid-infused treatments into South America.

Strategic Three-Step Market Entry:

1. Direct-to-Customer Sales: Testing market entry now with direct shipments of CANNORDIC's products as prescription-based treatments to Brazilian customers. This initial phase aligns with local regulations, healthcare partners, and customer needs, introducing the CANNASEN® brand and portfolio.
2. Expansion and Regulatory Compliance: Following the engagement of GMP-certified Contract Manufacturing Organizations (CMOs), CANNORDIC will apply for Regulation 327 with ANVISA. Post-audit approval, the partnership will scale to bulk sales, enhancing our market presence significantly with the adapted brand portfolio. *This post-regulatory and production process is estimated at 12 months.
3. Veterinary Products Introduction: The strategy culminates in the launch of veterinary products, tailoring CANNORDIC's innovative solutions to the Brazilian market further expanding our product range.

Alberto Bigatao, Director at Pharma Avanti, stated, "Partnering with CANNORDIC represents a step forward in meeting the health needs of Brazilians with high-quality, innovative, and compliant cannabinoid solutions. CANNORDIC's product range perfectly matches the dynamics of our market, and we are excited about its potential."

Lone Henriksen, CEO of CS MEDICA, comments, "Pharma Avanti is a leading force in Brazil's pharmaceutical sector. With its robust network and deep regulatory expertise, it is positioning itself as an ideal partner for CANNORDIC's market penetration efforts, as we can't enter this complex, rapid-growing territory ourselves."